FANCE is altered in 1.49% of malignant solid tumor patients with FANCE Amplification present in 0.05% of all malignant solid tumor patients [4].

FANCE Amplification is an inclusion criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain FANCE Amplification and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

FANCE is altered in 0.51% of prostate adenocarcinoma patients [4].

FANCE Amplification is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain FANCE Amplification and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

FANCE is altered in 0.5% of prostate carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FANCE Amplification and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

FANCE is altered in 1.7% of ovarian carcinoma patients with FANCE Amplification present in 0.1% of all ovarian carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCE Amplification and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.12% of breast carcinoma patients with FANCE Amplification present in 0.02% of all breast carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCE Amplification and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [5].

FANCE is altered in 2.08% of colorectal carcinoma patients with FANCE Amplification present in 0.02% of all colorectal carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCE Amplification and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.82% of cervical carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCE Amplification and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

FANCE Amplification is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FANCE Amplification and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 1.29% of non-small cell lung carcinoma patients with FANCE Amplification present in 0.06% of all non-small cell lung carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.47% of adenocarcinoma of the gastroesophageal junction patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain FANCE Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 2.84% of endometrial carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 4.55% of fallopian tube carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE Amplification and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

FANCE is altered in 1.01% of head and neck squamous cell carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE Amplification and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

FANCE is altered in 1.19% of non-hodgkin lymphoma patients [4].

FANCE Amplification is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.9% of high grade ovarian serous adenocarcinoma patients with FANCE Amplification present in 0.14% of all high grade ovarian serous adenocarcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.44% of cholangiocarcinoma patients with FANCE Amplification present in 0.12% of all cholangiocarcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FANCE is altered in 1.52% of malignant ovarian epithelial tumor patients with FANCE Amplification present in 0.09% of all malignant ovarian epithelial tumor patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 0.74% of pancreatic adenocarcinoma patients with FANCE Amplification present in 0.08% of all pancreatic adenocarcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FANCE is altered in 0.73% of pancreatic carcinoma patients with FANCE Amplification present in 0.08% of all pancreatic carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FANCE is altered in 2.35% of bladder urothelial carcinoma patients with FANCE Amplification present in 0.07% of all bladder urothelial carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FANCE is altered in 2.18% of urothelial carcinoma patients with FANCE Amplification present in 0.06% of all urothelial carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FANCE is altered in 2.05% of malignant intestinal neoplasm patients with FANCE Amplification present in 0.02% of all malignant intestinal neoplasm patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FANCE is altered in 1.77% of esophageal carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 2.01% of gastric carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FANCE is altered in 0.81% of gastrointestinal stromal tumor patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 1.57% of malignant esophagogastric neoplasm patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 2.01% of malignant gastric neoplasm patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 1.14% of malignant small intestinal neoplasm patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 5.26% of mantle cell lymphoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FANCE is altered in 1.41% of small cell lung carcinoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FANCE is altered in 0.31% of soft tissue sarcoma patients [4].

FANCE Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FANCE Amplification is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE Amplification and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].